- Home
- SEE vs IONS Comparison
SEE vs IONS Comparison
Compare SEE & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEE
- IONS
- Stock Information
- Founded
- SEE 1960
- IONS 1989
- Country
- SEE United States
- IONS United States
- Employees
- SEE N/A
- IONS N/A
- Industry
- SEE Major Chemicals
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- SEE Industrials
- IONS Health Care
- Exchange
- SEE Nasdaq
- IONS Nasdaq
- Market Cap
- SEE 5.3B
- IONS 6.0B
- IPO Year
- SEE N/A
- IONS 1991
- Fundamental
- Price
- SEE $35.49
- IONS $32.68
- Analyst Decision
- SEE Buy
- IONS Buy
- Analyst Count
- SEE 13
- IONS 18
- Target Price
- SEE $40.00
- IONS $62.00
- AVG Volume (30 Days)
- SEE 1.2M
- IONS 1.5M
- Earning Date
- SEE 02-25-2025
- IONS 02-19-2025
- Dividend Yield
- SEE 2.26%
- IONS N/A
- EPS Growth
- SEE 26.45
- IONS N/A
- EPS
- SEE 2.72
- IONS N/A
- Revenue
- SEE $5,397,300,000.00
- IONS $803,067,000.00
- Revenue This Year
- SEE N/A
- IONS N/A
- Revenue Next Year
- SEE $0.99
- IONS $10.85
- P/E Ratio
- SEE $13.10
- IONS N/A
- Revenue Growth
- SEE N/A
- IONS 30.57
- 52 Week Low
- SEE $30.87
- IONS $31.40
- 52 Week High
- SEE $41.14
- IONS $52.49
- Technical
- Relative Strength Index (RSI)
- SEE 58.33
- IONS 40.58
- Support Level
- SEE $34.22
- IONS $31.40
- Resistance Level
- SEE $34.83
- IONS $35.37
- Average True Range (ATR)
- SEE 0.72
- IONS 1.31
- MACD
- SEE 0.23
- IONS -0.23
- Stochastic Oscillator
- SEE 95.29
- IONS 29.09
About SEE Sealed Air Corporation
Sealed Air is organized via two reporting segments. Food care includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Product care includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.